Get started
Author

Chiara Carlotta Pircher

Observed names: C. Pircher, C.C. Pircher, Chiara C. Pircher, Chiara Pircher, Pircher Chiara, Pircher, Chiara, Pircher, Chiara Carlotta
ORCID: 0000-0001-8173-824X
Observed ORCID: 0000-0001-8173-824X
OpenAlex ID: A5071330516
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial
2018 · Michele Reni, Gianpaolo Balzano, et al. · ˜The œLancet. Gastroenterology & hepatology · 258
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
2024 · Federico Nichetti, Simone Rota, et al. · JAMA Network Open · 136
PDF
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
2018 · Michele Reni, Silvia Zanon, et al. · ˜The œLancet. Gastroenterology & hepatology · 70
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
2018 · Michele Reni, Silvia Zanon, et al. · European Journal of Cancer · 59
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
2022 · Giuseppe Procopio, Mélanie Claps, et al. · Tumori Journal · 51
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023 · Arsela Prelaj, Edoardo Gregorio Galli, et al. · Frontiers in Oncology · 39
PDF
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
2021 · Pierangela Sepe, Arianna Ottini, et al. · Cancers · 34
PDF
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
2022 · Giovanni Randon, Giulia Maddalena, et al. · JCO Precision Oncology · 31
PDF
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
2024 · Giovanni Randon, Sara Lonardi, et al. · The Lancet Oncology · 27
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy
2025 · Taotao Sheng, Raghav Sundar, et al. · Gut · 25
PDF
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study
2020 · Federico Nichetti, Marta Bini, et al. · ESMO Open · 18
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024 · Monica Niger, Federico Nichetti, et al. · BMC Cancer · 17
PDF
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
2021 · Arsela Prelaj, Chiara Carlotta Pircher, et al. · Cancers · 16
PDF
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
2025 · Alessandra Raimondi, Gabriele Tinè, et al. · Journal of Clinical Oncology · 15
PDF
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
2025 · Margherita Rimini, Lorenzo Fornaro, et al. · Liver International · 13
PDF
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index
2025 · Mara Persano, Margherita Rimini, et al. · Liver International · 11
PDF
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
2024 · S. Berenice Urtecho, Leonardo Provenzano, et al. · Lung Cancer · 11
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
2024 · Margherita Rimini, Eleonora Loi, et al. · Targeted Oncology · 11
PDF
Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study
2022 · Monica Niger, Federico Nichetti, et al. · International Journal of Cancer · 11
PDF
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
2024 · Federica Lo Prinzi, Francesca Salani, et al. · The Oncologist · 10
PDF
Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?
2023 · Héloïse Bourien, Chiara Carlotta Pircher, et al. · Cancers · 10
PDF
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2
2023 · Sara Pusceddu, Francesca Corti, et al. · Journal of Hematology & Oncology · 9
PDF
A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).
2021 · Giuseppe Procopio, Chiara Pircher, et al. · Journal of Clinical Oncology · 9
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
2022 · Monica Niger, Federico Nichetti, et al. · Molecular Oncology · 8
PDF
A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
2021 · Giuseppe Procopio, Melanie Claps, et al. · Journal of Clinical Oncology · 8
Works count: 86
Citation count: 988
H-index: 14
I10-index: 21
Year
Topic
Type